Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2– breast cancer
Authors:
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast CancerNew England Journal of Medicine, 2025
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerNew England Journal of Medicine, 2025
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)The Breast, 2024
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2022
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialJournal of Clinical Oncology, 2022
- The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerCancer Discovery, 2020
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer PatientsClinical Cancer Research, 2018
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerScience Translational Medicine, 2015